Ablexis Announces Licensing of the AlivaMab Mouse to Five Prime Therapeutics

BURLINGAME, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The non-exclusive license grants Five Prime rights to use the AlivaMab Mouse for antibody drug discovery and development. ÔÇťAblexis is … Continued

Read More